TL;DR: Aetna, a CVS Health company, modified CPB 1044 covering daprodustat (Jesduvroq) for anemia in chronic kidney disease, effective January 29, 2026. Here's what billing teams need to do.
This update to the Aetna daprodustat coverage policy tightens the criteria around HCPCS code J0889 — the billing code for oral daprodustat — and makes the hemoglobin thresholds explicit for both initial and continuation approval. If your practice or dialysis facility bills J0889 for Aetna commercial members, this policy governs your prior authorization requirements and medical necessity documentation starting January 29, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Daprodustat (Jesduvroq) — CPB 1044 |
| Policy Code | CPB 1044 Aetna system |
| Change Type | Modified |
| Effective Date | January 29, 2026 |
| Impact Level | High — dialysis facilities and nephrology practices billing J0889 |
| Specialties Affected | Nephrology, dialysis facilities, internal medicine, RCM teams managing ESRD billing |
| Key Action | Confirm every active J0889 claim has a pre-treatment hemoglobin ≤ 11 g/dL and a TSAT ≥ 20% on file before submitting to Aetna commercial plans |
Aetna Daprodustat Coverage Criteria and Medical Necessity Requirements 2026
Aetna's coverage policy for daprodustat (Jesduvroq) under CPB 1044 is narrow by design. Two hard criteria must both be met before Aetna considers the drug medically necessary for initial approval.
First, the member must have been receiving dialysis for at least four months. Second, the pre-treatment hemoglobin level must be at or below 11 g/dL. Both conditions are required — not one or the other.
The hemoglobin threshold is the one most likely to trip up your team. The policy explicitly excludes hemoglobin values drawn after a recent transfusion. If your documentation reflects a post-transfusion lab, Aetna will not count it. You need a clean, pre-transfusion value at or below 11 g/dL.
Iron status is the other documentation gap that causes claim denial. Before Aetna approves daprodustat billing, the member must have a serum transferrin saturation (TSAT) level at or above 20% drawn within the prior three months — or must be actively receiving iron therapy. This applies at initial approval and at every continuation request. No TSAT on file, no approval.
One more hard rule: members cannot use Jesduvroq at the same time as erythropoiesis stimulating agents (ESAs). If your records show concurrent ESA use, the prior authorization will be denied. This is not a gray area in the policy.
For continuation of therapy, the hemoglobin threshold loosens slightly. Aetna considers continued daprodustat therapy medically necessary when the current hemoglobin is below 12 g/dL. The same TSAT and iron therapy requirements apply. Same ESA exclusion applies.
This policy applies to Aetna commercial medical plans only. For Medicare criteria — which are handled differently, including separate reimbursement rules — Aetna directs providers to its Medicare Part B criteria page. Don't assume commercial and Medicare criteria are the same here. They're not.
Aetna Daprodustat Exclusions and Non-Covered Indications
Aetna's position on off-label use of daprodustat is clear. Any indication outside of anemia due to chronic kidney disease in adult dialysis patients is considered experimental, investigational, or unproven.
That means pre-dialysis CKD patients are not covered under this policy. Non-dialysis CKD is a meaningful population — and a common area where off-label prescribing happens. If you bill J0889 for a member who hasn't been on dialysis for at least four months, expect a denial.
Pediatric use is also not covered under CPB 1044. The policy specifies adult members only. If your facility treats adolescent dialysis patients and a prescriber orders Jesduvroq, you're outside this policy's coverage boundary.
There is no coverage pathway for experimental or compassionate-use billing under this policy. If a prescriber believes the drug is warranted outside the stated criteria, that's a medical necessity appeal conversation — not a billing workaround.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Anemia due to CKD — adult on dialysis ≥ 4 months, Hgb ≤ 11 g/dL at initiation | Covered | J0889, D63.1 | Prior auth required; TSAT ≥ 20% or iron therapy required; no concurrent ESA use |
| Continuation of therapy — adult on dialysis, current Hgb < 12 g/dL | Covered | J0889, D63.1 | Same iron and ESA requirements apply; post-transfusion Hgb values excluded |
| Anemia due to CKD — non-dialysis (pre-dialysis) patients | Not Covered | J0889, D63.1 | Dialysis requirement not met |
| Anemia due to CKD — pediatric patients | Not Covered | J0889, D63.1 | Policy limited to adult members only |
| All other indications (off-label use) | Experimental / Not Covered | J0889 | Considered investigational or unproven by Aetna |
| Concurrent use with ESAs | Not Covered | J0889 | Expressly excluded regardless of other criteria |
Aetna Daprodustat Billing Guidelines and Action Items 2026
This policy was modified on January 29, 2026. If you're billing J0889 for Aetna commercial members, these steps should already be in motion.
| # | Action Item |
|---|---|
| 1 | Audit all active Jesduvroq prior authorizations against the updated criteria. Confirm each auth on file reflects a documented dialysis start date at least four months before initiation. If your records show dialysis duration but no explicit start date, get that documentation now. |
| 2 | Pull TSAT labs for every active Jesduvroq patient before the next billing cycle. The TSAT must be at or above 20% within the prior three months — or you need documented active iron therapy. A missing TSAT is one of the fastest paths to a claim denial under this policy. |
| 3 | Flag every case with a recent transfusion in the chart. The policy excludes post-transfusion hemoglobin values for both initial approval and continuation. If your pre-treatment or current Hgb was drawn after a transfusion, you need a repeat draw. Don't submit until you have a clean value. |
| 4 | Check for concurrent ESA orders before submitting any J0889 claim. Run a medication reconciliation step in your workflow. Concurrent ESA use voids the approval. If a patient transitions from an ESA to Jesduvroq, confirm the ESA was discontinued before billing begins. |
| 5 | Update your continuation-of-therapy documentation workflow. The continuation threshold is hemoglobin below 12 g/dL — not the 11 g/dL threshold used at initiation. Your team needs to know these are two different numbers. Build that into your PA renewal checklist. |
| 6 | Separate your commercial and Medicare billing workflows for J0889. CPB 1044 governs commercial plans only. Medicare has its own criteria, and they differ. If your revenue cycle team uses a single workflow for both, split them. Mixing criteria is a reliable way to generate avoidable denials. |
| 7 | Review any claims billed for non-dialysis CKD patients. Pre-dialysis anemia is not covered under this policy. If any J0889 claims went out for patients not yet on dialysis, review those for potential recoupment exposure. Talk to your compliance officer if you find prior claims in this category. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Daprodustat Under CPB 1044
Key HCPCS Code — Covered When Selection Criteria Are Met
| Code | Type | Description |
|---|---|---|
| J0889 | HCPCS | Daprodustat, oral, 1 mg (for ESRD on dialysis) |
J0889 is the primary billing code for daprodustat reimbursement under this policy. Every J0889 claim submitted to Aetna commercial plans must be supported by the documentation outlined in CPB 1044 — dialysis duration, hemoglobin level, TSAT, and ESA exclusion.
Key ICD-10-CM Diagnosis Code
| Code | Description |
|---|---|
| D63.1 | Anemia in chronic kidney disease |
D63.1 is the diagnosis code that ties the J0889 claim to the covered indication. Make sure this code is present on every daprodustat claim. A claim submitted without D63.1 — or with a non-CKD anemia code — will not map to the covered indication under this policy.
Related Dialysis CPT Codes (CPT 90935–90999)
These codes appear in CPB 1044 as related codes. They reflect the full range of dialysis procedure codes — CPT 90935 through CPT 90999 — covering hemodialysis, peritoneal dialysis, and related services. Aetna references these codes in the context of the policy because dialysis status is a coverage prerequisite for J0889.
Your dialysis billing and your Jesduvroq billing are linked from a documentation standpoint. If the dialysis codes in the member's history don't support at least four months of treatment, the J0889 prior authorization won't hold.
| Code Range | Type | Description |
|---|---|---|
| 90935–90999 | CPT | Dialysis services (hemodialysis, peritoneal dialysis, and related procedures) |
The full list runs CPT 90935, 90936, 90937, 90938, 90939, 90940, 90941, 90942, 90943, 90944, 90945, 90946, 90947, 90948, 90949, 90950, 90951, 90952, 90953, 90954, 90955, 90956, 90957, 90958, 90959, 90960, 90961, 90962, 90963, 90964, 90965, 90966, 90967, 90968, 90969, 90970, 90971, 90972, 90973, 90974, 90975, 90976, 90977, 90978, 90979, 90980, 90981, 90982, 90983, 90984, 90985, 90986, 90987, 90988, 90989, 90990, 90991, 90992, 90993, 90994, 90995, 90996, 90997, 90998, 90999.
If you're auditing a patient's eligibility for daprodustat, cross-referencing their dialysis claims against this code set is a solid starting point for establishing the four-month requirement.
Get the Full Picture for CPT 90935
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.